 | • レポートコード：MRC2202A099 • 出版社/出版日：Mordor Intelligence / 2022年1月28日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Team User | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の狭心症治療薬の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療クラス別（ベータ遮断薬、カルシウムチャネル遮断薬、硝酸塩、アンジオテンシン変換酵素阻害剤（ACE阻害剤）、抗血小板）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向などを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の狭心症治療薬市場規模：治療クラス別（ベータ遮断薬、カルシウムチャネル遮断薬、硝酸塩、アンジオテンシン変換酵素阻害剤（ACE阻害剤）、抗血小板） ・世界の狭心症治療薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Amgen、Bayer AG、Eli Lilly and Company、Gilead Sciences、GlaxoSmithKline Plc.、Merck & Co., Inc.、Novartis AG、Otsuka Pharmaceutical Co. Ltd、Pfizer Inc.、Sanofi） ・市場機会・将来傾向 |
Lifestyle diseases and their chronic nature is among the pivotal reason for the high cardiovascular-related disorders globally. As per the Nesia Foundation Hospital, globally, about 14.2 million people between the age group 30-69 years, die prematurely from lifestyle disorders such as diabetes, arteriosclerosis, high cholesterol, stroke, nephritis, cancer, and several others. As per several published data on lifestyle-related diseases, women have more atypical signs of heart attack more often than men. In addition, in several cases, there is increased misdiagnosis or delayed diagnosis which eliminate the likeliness to receive immediate life-saving treatment of primary angioplasty and stents. The increasing burden of lifestyle diseases directly impacts the socio-economic aspects of nations globally, where appropriate actions for their management is the need of the moment. Thus, increasing burden of lifestyle diseases majorly drives the demand and need for angina pectoris drugs market.
Key Market Trends
Beta Blockers is Expected to Hold Smallest Share of Global Angina Pectoris Drugs Market, Over the forecast period
Beta blockers work by blocking the effect of adrenaline on the heart by providing benefits such as Slowing of the heart rate and reducing the force of heart muscle contraction. In patients with stable angina caused by CAD, beta blockers are considered first-line therapy. Beta Blockers has the smallest share in the market as the majority of beta-blocker drugs are predominately generic with key patent expirations impacting GlaxoSmithKline’s Coreg and AstraZeneca’s Toprol. Post Pfizer’s Norvasc patent being determined invalid in 2007, the Calcium Antagonist market is predominantly generic as well.
North America Region Holds the Largest Market Share of Angina Pectoris Drugs Market
North America dominates the Angina Pectoris Drugs market due to the established healthcare infrastructure, increased adoption of therapeutics and presence of key manufacturers in the U.S are responsible for its large share. Ischaemic heart disease is a major cause of death and disability worldwide, while angina represents its most common symptom. It is estimated that approximately 9 million patients in the USA suffer from angina and its treatment is challenging. Moreover, increasing incidence of cardiac disorders due to the sedentary lifestyle and favorable regulatory initiatives are fueling the market growth.
Competitive Landscape
Some of the prominent industry players operating in total Angina Pectoris Drugs market include Amgen, Bayer AG, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline Plc and Merck & Co., Inc. Development of advanced products for better outcomes and rigorous marketing are some of the competitive strategies adopted by market players.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Lifestyles Diseases
4.2.2 Technological Advancements towards Personalized Cardiovascular Medicines
4.2.3 Augmentation of Novel Drug Delivery Systems
4.3 Market Restraints
4.3.1 Increasing Adoption of Minimally Invasive Surgeries
4.3.2 Side Effects Associated with Certain Drug Classes
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Therapeutic Class
5.1.1 Beta Blockers
5.1.2 Calcium Channel Blockers
5.1.3 Nitrates
5.1.4 Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
5.1.5 Anti-Platelets
5.1.6 Others
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen
6.1.2 Bayer AG
6.1.3 Eli Lilly and Company
6.1.4 Gilead Sciences
6.1.5 GlaxoSmithKline Plc.
6.1.6 Merck & Co., Inc.
6.1.7 Novartis AG
6.1.8 Otsuka Pharmaceutical Co. Ltd
6.1.9 Pfizer Inc.
6.1.10 Sanofi
7 MARKET OPPORTUNITIES AND FUTURE TRENDS